1. Vascular Targeting Agents as Cancer Therapeutics
   Philip E. Thorpe, 2004, Clinical Cancer Research CrossRef
2. Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate
   Ian G. Kirwan et al, 2004, Clinical Cancer Research CrossRef
3. Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma
   Tae Jin Kim et al, 2007, Cancer Research CrossRef
4. Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow
   James P. Stevenson et al, 2003, Journal of Clinical Oncology CrossRef
5. Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor Vascularity
   Howard W. Salmon et al, 2006, Clinical Cancer Research CrossRef
6. Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate
   Helen L. Anderson et al, 2003, Journal of Clinical Oncology CrossRef